Specify a stock or a cryptocurrency in the search bar to get a summary
Hinova Pharmaceuticals Inc. A
688302Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer. The company was founded in 2013 and is headquartered in Chengdu, China. Address: Building 1, Rongyao Building, Chengdu, China, 610041
Analytics
WallStreet Target Price
484.29 CNYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 688302
Dividend Analytics 688302
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 688302
Stock Valuation 688302
Financials 688302
Results | 2019 | Dynamics |